DE69232002T2 - Immunoassays unter Verwendung von markierten Hapten-Analogen - Google Patents
Immunoassays unter Verwendung von markierten Hapten-AnalogenInfo
- Publication number
- DE69232002T2 DE69232002T2 DE69232002T DE69232002T DE69232002T2 DE 69232002 T2 DE69232002 T2 DE 69232002T2 DE 69232002 T DE69232002 T DE 69232002T DE 69232002 T DE69232002 T DE 69232002T DE 69232002 T2 DE69232002 T2 DE 69232002T2
- Authority
- DE
- Germany
- Prior art keywords
- label
- analogue
- immunoassay
- groups
- phenobarbital
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000003018 immunoassay Methods 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 50
- 229940079593 drug Drugs 0.000 claims abstract description 49
- 150000001412 amines Chemical class 0.000 claims abstract description 23
- 150000001469 hydantoins Chemical class 0.000 claims abstract description 12
- 102000004190 Enzymes Human genes 0.000 claims description 38
- 108090000790 Enzymes Proteins 0.000 claims description 38
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 37
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 33
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical group C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 33
- 229960002695 phenobarbital Drugs 0.000 claims description 30
- 229960002036 phenytoin Drugs 0.000 claims description 27
- 125000005647 linker group Chemical group 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 19
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical group O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 16
- 239000011324 bead Substances 0.000 claims description 14
- 229940091173 hydantoin Drugs 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 9
- -1 ethylene, butylene, pentylene, octylene Chemical group 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 125000004185 ester group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229940053195 antiepileptics hydantoin derivative Drugs 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000003636 chemical group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 abstract description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 62
- 238000002360 preparation method Methods 0.000 description 57
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 53
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 36
- 229940088598 enzyme Drugs 0.000 description 34
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 238000000502 dialysis Methods 0.000 description 24
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 21
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000975 dye Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000000758 substrate Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 239000003446 ligand Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 108010015776 Glucose oxidase Proteins 0.000 description 9
- 239000004366 Glucose oxidase Substances 0.000 description 9
- 229940116332 glucose oxidase Drugs 0.000 description 9
- 235000019420 glucose oxidase Nutrition 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 8
- 238000009739 binding Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 108010032595 Antibody Binding Sites Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000007480 spreading Effects 0.000 description 7
- 238000003892 spreading Methods 0.000 description 7
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000012875 competitive assay Methods 0.000 description 6
- 229960003330 pentetic acid Drugs 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 239000012064 sodium phosphate buffer Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 5
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 5
- 239000007993 MOPS buffer Substances 0.000 description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 4
- 239000007987 MES buffer Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002967 competitive immunoassay Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229940014800 succinic anhydride Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 3
- 150000001414 amino alcohols Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003283 colorimetric indicator Substances 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000012637 allosteric effector Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- LXLLLPSNNRGWJH-UHFFFAOYSA-N benzyl n-(6-aminohexyl)carbamate Chemical compound NCCCCCCNC(=O)OCC1=CC=CC=C1 LXLLLPSNNRGWJH-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003118 drug derivative Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- 229940070710 valerate Drugs 0.000 description 2
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- ZRJMDLPRCZJBRD-UHFFFAOYSA-N 3-(1-oxo-1-piperazin-1-ylpentan-2-yl)-5,5-diphenylimidazolidine-2,4-dione Chemical compound C1CNCCN1C(=O)C(CCC)N(C1=O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 ZRJMDLPRCZJBRD-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- KWVMZHNPNLYOJD-UHFFFAOYSA-N 4-[2-[5-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)pentanoylamino]ethoxy]-4-oxobutanoic acid Chemical compound O=C1N(CCCCC(=O)NCCOC(=O)CCC(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 KWVMZHNPNLYOJD-UHFFFAOYSA-N 0.000 description 1
- BFYSMJLXRUKHFS-UHFFFAOYSA-N 4-[3-[5-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)pentanoylamino]propylamino]-4-oxobutanoic acid Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(CCCCC(=O)NCCCNC(=O)CCC(O)=O)C1=O BFYSMJLXRUKHFS-UHFFFAOYSA-N 0.000 description 1
- YGXLZJGQTGARDZ-UHFFFAOYSA-N 4-[4-[5-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)pentanoyl]piperazin-1-yl]-4-oxobutanoic acid Chemical compound C1CN(C(=O)CCC(=O)O)CCN1C(=O)CCCCN1C(=O)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)NC1=O YGXLZJGQTGARDZ-UHFFFAOYSA-N 0.000 description 1
- IETVJPVMCGQMFW-UHFFFAOYSA-N 4-[4-[5-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)pentanoyl]piperazin-1-yl]-4-oxobutanoic acid Chemical compound O=C1C(CC)(C=2C=CC=CC=2)C(=O)NC(=O)N1CCCCC(=O)N1CCN(C(=O)CCC(O)=O)CC1 IETVJPVMCGQMFW-UHFFFAOYSA-N 0.000 description 1
- YFJMPVUGZUTBFO-UHFFFAOYSA-N 4-[6-[5-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)pentanoylamino]hexylamino]-4-oxobutanoic acid Chemical compound O=C1N(CCCCC(=O)NCCCCCCNC(=O)CCC(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 YFJMPVUGZUTBFO-UHFFFAOYSA-N 0.000 description 1
- AHFWUUSNMMFTKI-UHFFFAOYSA-N 5-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)-n-(2-hydroxyethyl)pentanamide Chemical compound O=C1N(CCCCC(=O)NCCO)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 AHFWUUSNMMFTKI-UHFFFAOYSA-N 0.000 description 1
- IIOGHFGMYZHJPP-UHFFFAOYSA-N 5-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)pentanoic acid Chemical compound O=C1N(CCCCC(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 IIOGHFGMYZHJPP-UHFFFAOYSA-N 0.000 description 1
- SYKAZMZQEPFIEO-UHFFFAOYSA-N 5-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)-n-(2-hydroxyethyl)pentanamide Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(CCCCC(=O)NCCO)C1=O SYKAZMZQEPFIEO-UHFFFAOYSA-N 0.000 description 1
- GHUXHFJCGNEOLW-UHFFFAOYSA-N 5-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)pentanoic acid Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(CCCCC(O)=O)C1=O GHUXHFJCGNEOLW-UHFFFAOYSA-N 0.000 description 1
- KKUPBFNQTHGADL-UHFFFAOYSA-N 5-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)pentanoyl chloride Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(CCCCC(Cl)=O)C1=O KKUPBFNQTHGADL-UHFFFAOYSA-N 0.000 description 1
- VJNADEBAPLHARN-UHFFFAOYSA-N Br.O=C1C(CC)(C=2C=CC=CC=2)C(=O)NC(=O)N1CCCCC(=O)N1CCNCC1 Chemical compound Br.O=C1C(CC)(C=2C=CC=CC=2)C(=O)NC(=O)N1CCCCC(=O)N1CCNCC1 VJNADEBAPLHARN-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- TZSLWQVJSTVTMP-UHFFFAOYSA-N benzyl 2,4-diaminobutanoate Chemical compound NCCC(N)C(=O)OCC1=CC=CC=C1 TZSLWQVJSTVTMP-UHFFFAOYSA-N 0.000 description 1
- OXZSVNMAOOMREC-UHFFFAOYSA-N benzyl 4-[5-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)pentanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC=2C=CC=CC=2)CCN1C(=O)CCCCN(C1=O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 OXZSVNMAOOMREC-UHFFFAOYSA-N 0.000 description 1
- CZWYESODPJCZSY-UHFFFAOYSA-N benzyl 4-[5-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)pentanoyl]piperazine-1-carboxylate Chemical compound O=C1C(CC)(C=2C=CC=CC=2)C(=O)NC(=O)N1CCCCC(=O)N(CC1)CCN1C(=O)OCC1=CC=CC=C1 CZWYESODPJCZSY-UHFFFAOYSA-N 0.000 description 1
- JXWABCYGGVHAHB-UHFFFAOYSA-N benzyl n-(3-aminopropyl)carbamate Chemical compound NCCCNC(=O)OCC1=CC=CC=C1 JXWABCYGGVHAHB-UHFFFAOYSA-N 0.000 description 1
- FPZYKXIQAFSJBL-UHFFFAOYSA-N benzyl n-[3-[5-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)pentanoylamino]propyl]carbamate Chemical compound O=C1C(CC)(C=2C=CC=CC=2)C(=O)NC(=O)N1CCCCC(=O)NCCCNC(=O)OCC1=CC=CC=C1 FPZYKXIQAFSJBL-UHFFFAOYSA-N 0.000 description 1
- OLFPNNKQTLQAEK-UHFFFAOYSA-N benzyl n-[6-[5-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)pentanoylamino]hexyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NCCCCCCNC(=O)CCCCN(C1=O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 OLFPNNKQTLQAEK-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012992 electron transfer agent Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- UBMRMPDCVDGINV-UHFFFAOYSA-N methyl 5-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)pentanoate Chemical compound C=1C=CC=CC=1C1(CC)C(O)=NC(=O)N(CCCCC(=O)OC)C1=O UBMRMPDCVDGINV-UHFFFAOYSA-N 0.000 description 1
- RAVVJKCSZXAIQP-UHFFFAOYSA-N methyl 5-bromopentanoate Chemical compound COC(=O)CCCCBr RAVVJKCSZXAIQP-UHFFFAOYSA-N 0.000 description 1
- BISVVKSTXIKDMH-UHFFFAOYSA-N n-(3-aminopropyl)-5-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)pentanamide;hydrobromide Chemical compound Br.C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(CCCCC(=O)NCCCN)C1=O BISVVKSTXIKDMH-UHFFFAOYSA-N 0.000 description 1
- AIQODGUCINLCAT-UHFFFAOYSA-N n-(6-aminohexyl)-5-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)pentanamide Chemical compound O=C1N(CCCCC(=O)NCCCCCCN)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 AIQODGUCINLCAT-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/816—Alkaloids, amphetamines, and barbiturates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Anesthesiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71232891A | 1991-06-07 | 1991-06-07 | |
| US85143692A | 1992-03-16 | 1992-03-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69232002D1 DE69232002D1 (de) | 2001-09-20 |
| DE69232002T2 true DE69232002T2 (de) | 2002-06-06 |
Family
ID=27108808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69232002T Expired - Lifetime DE69232002T2 (de) | 1991-06-07 | 1992-06-02 | Immunoassays unter Verwendung von markierten Hapten-Analogen |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5601994A (fr) |
| EP (1) | EP0517327B1 (fr) |
| JP (1) | JP3190730B2 (fr) |
| AT (1) | ATE204385T1 (fr) |
| DE (1) | DE69232002T2 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2960628B2 (ja) * | 1992-06-26 | 1999-10-12 | イーストマン コダック カンパニー | 標識サイロニンハプテン類似体を用いたイムノアッセイ |
| ATE161962T1 (de) * | 1992-08-07 | 1998-01-15 | Johnson & Johnson Clin Diag | Immunoassays unter verwendung von, mit meerrettich-peroxidase markierten carbamazepin- analogen |
| US5565326A (en) | 1994-05-31 | 1996-10-15 | Johnson & Johnson Clinical Diagnostics, Inc. | Separation-free specific binding assays using anti-inhibitor antibodies |
| US5650324A (en) | 1994-05-31 | 1997-07-22 | Johnson & Johnson Clinical Diagnostics, Inc. | Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase |
| US5589344A (en) * | 1994-06-15 | 1996-12-31 | Johnson & Johnson Clinical Diagnostics, Inc. | Test kit and method for competitive specific binding assay |
| AU697785B2 (en) | 1994-07-19 | 1998-10-15 | Johnson & Johnson Clinical Diagnostics, Inc. | Analytical element,composition and method using modified apo-horseradish peroxidase |
| ES2167278B1 (es) * | 2000-10-24 | 2003-08-16 | Univ Murcia | Enzima con actividad peroxidasa aislada de la alcachofa (cynara scolymus, l.) procedimiento para su aislamiento y purificacion y aplicaciones. |
| US8133743B2 (en) | 2007-10-19 | 2012-03-13 | Roche Diagnostics Operations, Inc. | Phenobarbital derivatives useful in immunoassay |
| CN104736561B (zh) | 2012-08-21 | 2018-06-12 | 詹森药业有限公司 | 帕潘立酮的抗体及其用途 |
| AU2013305938B2 (en) | 2012-08-21 | 2017-08-17 | Saladax Biomedical Inc. | Antibodies to paliperidone haptens and use thereof |
| CN104736565B (zh) | 2012-08-21 | 2019-03-12 | 詹森药业有限公司 | 利培酮半抗原的抗体及其用途 |
| JP6389177B2 (ja) | 2012-08-21 | 2018-09-12 | ヤンセン ファーマシューティカ エヌ．ベー． | オランザピンハプテンに対する抗体及びその使用 |
| CN107043424B (zh) | 2012-08-21 | 2021-03-16 | 詹森药业有限公司 | 利培酮的抗体及其用途 |
| JP6949025B2 (ja) | 2015-12-17 | 2021-10-13 | ヤンセン ファーマシューティカ エヌ．ベー． | リスペリドンに対する抗体及びその使用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875011A (en) * | 1972-11-06 | 1975-04-01 | Syva Co | Enzyme immunoassays with glucose-6-phosphate dehydrogenase |
| US4065354A (en) * | 1974-10-10 | 1977-12-27 | Syva Company | Lysozyme conjugates for enzyme immunoassays |
| US4213964A (en) * | 1978-12-07 | 1980-07-22 | Miles Laboratories, Inc. | Diphenylhydantoin antibodies |
| IL59065A0 (en) * | 1979-01-18 | 1980-05-30 | Beecham Group Ltd | Hydantoin derivatives,their preparation pharmaceutical compositons containing them |
| US4404366A (en) * | 1980-05-06 | 1983-09-13 | Miles Laboratories, Inc. | Beta-galactosyl-umbelliferone-labeled hapten conjugates |
| NZ199629A (en) * | 1981-02-17 | 1984-11-09 | Abbott Lab | Fluorescent polarisation immunoassay and certain substituted carboxy fluoresceins |
| US4378428A (en) * | 1981-03-30 | 1983-03-29 | Baker Instruments Corporation | Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays |
| US4447529A (en) * | 1981-07-06 | 1984-05-08 | Miles Laboratories, Inc. | Preparing homogeneous specific binding assay element to avoid premature reaction |
| US4752568A (en) * | 1986-01-13 | 1988-06-21 | Eastman Kodak Company | Labeled hydantoin conjugate and its use in analytical element and immunoassays |
| CA1300499C (fr) * | 1987-08-03 | 1992-05-12 | Susan J. Danielson | Reactif insoluble dans l'eau, elements qui en contiennent et methode d'utilisation |
| DK0386644T3 (da) * | 1989-03-10 | 1997-10-13 | Hoffmann La Roche | Reagenser til bestemmelse af lægemidler |
| US5096838A (en) * | 1989-11-27 | 1992-03-17 | Abbott Laboratories | Barbiturate assay compositions and methods |
| US5162219A (en) * | 1990-06-18 | 1992-11-10 | Eastman Kodak Company | Preparation of amine-enriched proteins having an increased isoelectric point |
-
1992
- 1992-06-02 DE DE69232002T patent/DE69232002T2/de not_active Expired - Lifetime
- 1992-06-02 EP EP92201582A patent/EP0517327B1/fr not_active Expired - Lifetime
- 1992-06-02 AT AT92201582T patent/ATE204385T1/de active
- 1992-06-05 JP JP14600792A patent/JP3190730B2/ja not_active Expired - Fee Related
-
1994
- 1994-04-28 US US08/235,114 patent/US5601994A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0517327A3 (en) | 1993-05-05 |
| JPH0627108A (ja) | 1994-02-04 |
| ATE204385T1 (de) | 2001-09-15 |
| EP0517327B1 (fr) | 2001-08-16 |
| JP3190730B2 (ja) | 2001-07-23 |
| US5601994A (en) | 1997-02-11 |
| EP0517327A2 (fr) | 1992-12-09 |
| DE69232002D1 (de) | 2001-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69231382T2 (de) | Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden | |
| DE69232002T2 (de) | Immunoassays unter Verwendung von markierten Hapten-Analogen | |
| DE19621133A1 (de) | Bestimmungsverfahren mit oligomerisierten Rezeptoren | |
| DE69026851T2 (de) | Verfahren zur Erhöhung von Chemilumineszenz | |
| DE69032383T2 (de) | Heterogene Bindungstests | |
| DE69736382T2 (de) | Chemilumineszente zusammensetungen und ihre verwendung zum nachweis von wasserstoffperoxid | |
| EP0697021B1 (fr) | Derives photoactivables de la biotine et leur utilisation pour la suppression des interactions dans les dosages immunologiques | |
| DE69331570T2 (de) | Agglutinationstest unter Anwendung eines multivalenten Liganden | |
| DE69636013T2 (de) | Verfahren zum erlangen von rezeptor-freigabeligand (reland)-komplexen und testansätze | |
| DE69418501T2 (de) | Immunologische Bestimmung eines Antigens oder eines Haptens | |
| DE68921151T2 (de) | Substrat-Zusammensetzung für Alkali-Phosphatase sowie ihre Verwendung bei Testverfahren. | |
| DE69232162T2 (de) | Hapten-Analoge zur Verwendung in Immunoassays | |
| DE69007473T2 (de) | Katalysierte ablagerung von markierungsmittel. | |
| DE69016617T2 (de) | Gepufferte Waschzusammensetzung, Zusammensetzung zur Unlöslichmachung, Testsätze und Verfahren zu ihrer Verwendung. | |
| DE69323244T2 (de) | Immunotests unter Verwendung von markierten Thyronin-Analogen | |
| EP0233690B1 (fr) | Conjugué d'hydantoine marquée et son utilisation dans un élément d'analyse et dans les immuno-essais | |
| EP0992512B1 (fr) | Conjugué de cortisol réduit | |
| US5527709A (en) | Immunoassays with labeled thyronine hapten analogues | |
| DE69316112T2 (de) | Immunoassays unter Verwendung von, mit Meerrettich-Peroxidase markierten Carbamazepin-Analogen | |
| DE69232001T2 (de) | Markierte Hapten-Analoge zur Verwendung in Immunoassays | |
| EP0874994B1 (fr) | Determination des groupes terminaux acide sialique de la molecule transferrine humaine | |
| CA2062240A1 (fr) | Derives d'hydantoine marques pour des dosages immunologiques | |
| US5578457A (en) | Immunoassays with novel labeled carbamazepine hapten analogues | |
| DE69526143T2 (de) | Abtrennfreier, spezifischer Bindungsassay mit Anti-Inhibitor-Antikörpern | |
| DE69023182T2 (de) | Verbindung von Stoffen zu Polymerteilchen mittels dikationischen Äthern und diese enthaltende Kits. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN |
|
| 8364 | No opposition during term of opposition | ||
| R071 | Expiry of right |
Ref document number: 517327 Country of ref document: EP |